These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21625848)

  • 21. Regulation and function of IKK and IKK-related kinases.
    Häcker H; Karin M
    Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines.
    Tacchini L; De Ponti C; Matteucci E; Follis R; Desiderio MA
    Carcinogenesis; 2004 Nov; 25(11):2089-100. PubMed ID: 15240510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity.
    Mauro C; Zazzeroni F; Papa S; Bubici C; Franzoso G
    Methods Mol Biol; 2009; 512():169-207. PubMed ID: 19347278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe.
    Aggarwal BB; Vijayalekshmi RV; Sung B
    Clin Cancer Res; 2009 Jan; 15(2):425-30. PubMed ID: 19147746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using NF-κB as a molecular target for theranostics in radiation oncology research.
    Liu YC; Chiang IT; Hsu FT; Hwang JJ
    Expert Rev Mol Diagn; 2012 Mar; 12(2):139-46. PubMed ID: 22369374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear transcription factor-kappaB as a target for cancer drug development.
    Garg A; Aggarwal BB
    Leukemia; 2002 Jun; 16(6):1053-68. PubMed ID: 12040437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of NF-kappaB in hypoxia-induced gene expression.
    Taylor CT; Cummins EP
    Ann N Y Acad Sci; 2009 Oct; 1177():178-84. PubMed ID: 19845620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership.
    Dobrovolskaia MA; Kozlov SV
    Curr Cancer Drug Targets; 2005 Aug; 5(5):325-44. PubMed ID: 16101381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Curaxins: a new family of non-genotoxic multitargeted anticancer agents.
    Di Bussolo V; Minutolo F
    ChemMedChem; 2011 Dec; 6(12):2133-6. PubMed ID: 22038935
    [No Abstract]   [Full Text] [Related]  

  • 32. The complexity of NF-κB signaling in inflammation and cancer.
    Hoesel B; Schmid JA
    Mol Cancer; 2013 Aug; 12():86. PubMed ID: 23915189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the inflammatory pathways to enhance chemotherapy of cancer.
    Zhu Z; Zhong S; Shen Z
    Cancer Biol Ther; 2011 Jul; 12(2):95-105. PubMed ID: 21623164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 and the Carcinogenicity of Chronic Inflammation.
    Gudkov AV; Komarova EA
    Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27549311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation, NF-κB, and Chronic Diseases: How are They Linked?
    Kunnumakkara AB; Shabnam B; Girisa S; Harsha C; Banik K; Devi TB; Choudhury R; Sahu H; Parama D; Sailo BL; Thakur KK; Gupta SC; Aggarwal BB
    Crit Rev Immunol; 2020; 40(1):1-39. PubMed ID: 32421977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of hypoxia on cell death pathways.
    Lenihan CR; Taylor CT
    Biochem Soc Trans; 2013 Apr; 41(2):657-63. PubMed ID: 23514172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NF-kappa B as a target for cancer therapy.
    Melisi D; Chiao PJ
    Expert Opin Ther Targets; 2007 Feb; 11(2):133-44. PubMed ID: 17227230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer drugs designed by mother nature: ancient drugs but modern targets.
    Ichikawa H; Nakamura Y; Kashiwada Y; Aggarwal BB
    Curr Pharm Des; 2007; 13(33):3400-16. PubMed ID: 18045194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
    Russo MA; Sansone L; Carnevale I; Limana F; Runci A; Polletta L; Perrone GA; De Santis E; Tafani M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):171-85. PubMed ID: 25772175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents.
    Gupta SC; Kim JH; Kannappan R; Reuter S; Dougherty PM; Aggarwal BB
    Exp Biol Med (Maywood); 2011 Jun; 236(6):658-71. PubMed ID: 21565893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.